Cutera (CUTR) Upgraded by ValuEngine to “Strong-Buy”

Cutera (NASDAQ:CUTR) was upgraded by equities researchers at ValuEngine from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

Several other research analysts have also recently issued reports on the company. TheStreet cut Cutera from a “b-” rating to a “c+” rating in a research note on Tuesday, May 15th. BidaskClub raised Cutera from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 8th. Zacks Investment Research cut Cutera from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 18th. Stifel Nicolaus assumed coverage on Cutera in a research note on Monday, April 16th. They issued a “hold” rating and a $55.00 price target for the company. Finally, Stephens assumed coverage on Cutera in a research note on Tuesday, March 13th. They issued an “overweight” rating and a $60.00 price target for the company. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $46.67.

Get Cutera alerts:

Shares of Cutera opened at $44.20 on Friday, according to MarketBeat. The firm has a market cap of $556.29 million, a P/E ratio of 57.40, a P/E/G ratio of 1.70 and a beta of 0.48. Cutera has a 12 month low of $22.65 and a 12 month high of $56.05.

Cutera (NASDAQ:CUTR) last issued its quarterly earnings data on Tuesday, May 8th. The medical device company reported ($0.02) EPS for the quarter, missing the Zacks’ consensus estimate of $0.01 by ($0.03). The company had revenue of $34.10 million for the quarter, compared to the consensus estimate of $35.27 million. Cutera had a return on equity of 16.12% and a net margin of 18.54%. Cutera’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.07) earnings per share. analysts anticipate that Cutera will post 0.57 earnings per share for the current year.

In related news, Director David A. Gollnick sold 17,175 shares of the firm’s stock in a transaction dated Thursday, May 24th. The stock was sold at an average price of $39.37, for a total transaction of $676,179.75. Following the completion of the transaction, the director now owns 9,466 shares of the company’s stock, valued at $372,676.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David A. Gollnick sold 892 shares of the firm’s stock in a transaction dated Tuesday, May 29th. The shares were sold at an average price of $41.02, for a total value of $36,589.84. Following the transaction, the director now directly owns 9,466 shares of the company’s stock, valued at approximately $388,295.32. The disclosure for this sale can be found here. Corporate insiders own 11.60% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue bought a new position in Cutera during the fourth quarter valued at about $125,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in Cutera by 3,400.0% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,500 shares of the medical device company’s stock valued at $159,000 after buying an additional 3,400 shares in the last quarter. Alambic Investment Management L.P. bought a new position in Cutera during the fourth quarter valued at about $204,000. Teacher Retirement System of Texas bought a new position in Cutera during the fourth quarter valued at about $206,000. Finally, Rehmann Capital Advisory Group bought a new position in Cutera during the fourth quarter valued at about $222,000. 94.31% of the stock is owned by institutional investors and hedge funds.

Cutera Company Profile

Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Cutera (NASDAQ:CUTR)

Leave a Reply

Your email address will not be published. Required fields are marked *